Study of Daily Low-Methoxy Pectin Supplementation Effects on Inflammation, Gut Microbiome, and Metabolic Health in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease MASLD
Led by University of Nottingham · Updated on 2026-07-29
45
Participants Needed
3
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the effects of daily supplementation with Low-methoxy LM pectin, a dietary polysaccharide from citrus peels commonly found in the UK diet, on systemic inflammation and gut microbiota in adults recently diagnosed with Metabolic Dysfunction-Associated Steatotic Liver Disease MASLD. The study aims to understand how LM-pectin impacts inflammation pathways and metabolic indicators in people with MASLD by comparing it to a placebo. This research is a randomized, placebo-controlled dietary intervention led by the University of Nottingham.
Participants will take a daily supplement for 6 weeks, receiving either 15g of LM-pectin with 10g of cocoa powder or 10g of placebo with 10g of cocoa powder. Alongside this, 15 healthy volunteers will undergo MRI scans twice to validate MRI as a tool for assessing gut permeability and compare their results to MASLD participants. The study includes optional MRI scans for MASLD participants to assess liver fat and gut permeability.
During the study, participants will provide stool and fasting blood samples before and after the intervention. They will also have anthropometric measurements taken, including weight, height, waisthip ratio, and blood pressure, and undergo a FibroScan to evaluate liver health. The study will measure various blood inflammatory markers, metabolic indicators, liver enzymes, and changes in gut microbiome composition. Safety and genetic factors related to gut permeability will also be assessed, with all participation lasting 6 weeks.
CONDITIONS
Brief Title
The Impact of Pectin Supplementation on Systematic Inflammation Pathway, Gut Microbiome, and Metabolic Health in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Research Team
N
Noor K Al-Tameemi, PhD student candidate
G
Guruprasad P Aithal, Professor
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Patients with clinical diagnosis of MASLD having liver fat greater than 5% confirmed by recent tests such as FibroScan™, ultrasound, CT, or MRI
Willing and able to give informed consent
Aged 18 years or older with BMI between 18.5 and 39.9 kg/m2 and stable weight (gain or loss ≤ 3kg) over past 3 months
For diabetic participants, controlled blood glucose with HbA1c less than 7.0%
Able to undergo CAP-FibroScan™
For healthy participants in MRI scans: aged 18 years or older, willing and able to consent, with CAP less than 250 kPa within past 6 months
You will not qualify if you...
Allergy to soya, milk, chocolate, or pectin
Following a vegan diet
Having eating disorders or gastrointestinal conditions such as coeliac disease, IBS, IBD, gastroparesis
Chronic malnutrition
History of major surgery limiting participation, including intestinal or bariatric surgery
Use of antibiotics, antifungal medications, probiotics, or prebiotics within 90 days before the study
Taking immunosuppressants, amiodarone, or perhexiline
Following or planning to start a specialized weight loss diet or using weight loss medications or herbal products
History of side effects to probiotics or prebiotics
History or current psychiatric or neurological conditions (e.g., epilepsy)
Other liver abnormalities or metabolic diseases such as LALD, Wilson disease, or inborn errors of metabolism
Weight change exceeding 3 kg within 3 months
Uncontrolled diabetes, active cancer, or chronic infections
Symptoms of active infection
Excessive alcohol intake (more than 21 units/week for men, 14 units/week for women)
Pregnant, breastfeeding, or planning pregnancy
Participation in another trial within last 3 months
Contraindications for MRI (for MRI participants), such as pacemakers, defibrillators, metallic implants, or claustrophobia
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Supplementation Period
Duration - 6 weeks
Participants take a daily supplement of either LM-pectin with cocoa powder or placebo with cocoa powder for 6 weeks. Optional MRI scans may be performed to assess gut permeability and liver fat.
Multiple visits including sample collection and FibroScan™
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
BASIC_SCIENCE
Number of Arms
3
Similar Trials
Pilot Study of an AI Chatbot for Reducing Alcohol Use in Adults with Metabolic Alcohol-Related Liver Disease
Randomized Trial of Retatrutide and Tirzepatide in Adults with Metabolic Dysfunction-Associated Steatotic Liver Disease to Prevent Major Liver Outcomes
Phase 1 Study of Multiple Subcutaneous Injections of B1344 for Adults With Nonalcoholic Fatty Liver Disease NAFLD
Randomized Trial of Electronic Decision Support to Improve Care for Adults with Steatotic Liver Disease
SEC-HOPE Observational Study of Secukinumab Retention in Adults with Plaque Psoriasis and MASLD in Spain
Testing Resmetirom for Treating Metabolic Dysfunction-Associated Steatotic Liver Disease in Adults With HIV
Phase IIa Study to Assess the Effectiveness and Safety of HP515 Tablets for Adults With Non-Alcoholic Fatty Liver Disease
Study on How Faster Biological Aging Affects the Risk of Type 2 Diabetes in People With and Without Metabolic Liver Disease
Studying Heart Function Changes Using MRI and Echocardiography in Adults with Alcohol-Related Liver Cirrhosis Undergoing Transjugular Intrahepatic Portosystemic Shunt TIPSS Placement
Evaluating a New Electronic Health Record Alert for Detecting Advanced Fibrosis in Patients with Metabolic Dysfunction-associated Steatotic Liver Disease MASLD in Primary Care
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
The impact of pectin supplementation on systemic inflammation pathways, gut microbiome, and metabolic health in patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A study protocol for a randomised controlled trial.
Noor Kifah Al-Tameemi, Jane I Grove, Caroline L Hoad...